The True Nature of Danger Behind IP Waiver Proposal
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent Contractors
Cracking Down on Speaker Programs
Dynamic Compliance: The Best Defense for Pharma
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
Biotech Performance Glance—and Promising Ripples for Recovery
If Non-Formulary Hospital, Price May Not Be the Rx
When It Comes To DE&I, Silence Is Deafening
Asia’s Rise in The Global Pharma Industry
Rewriting European Regulations on Rare Disease Treatments
Pharmaceutical Executive, July 2022 Issue (PDF)
Orphan Drugs: From Niche to Mainstream
FDA Advances Quality Initiatives to Combat Drug Shortages